Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


July 02, 2015 6:42 AM ET

Biotechnology

Company Overview of HemoShear, LLC

Company Overview

HemoShear, LLC, a biotechnology research company, develops and creates human-relevant systems that replicate the biology of organ systems and diseases in drug discovery and development. It conducts various experimental programs using human or animal primary cells; recreates in vivo hemodynamic conditions; cultures multiple cell types together to restore native biology; uses primary cells in physiologically accurate media conditions; creates physiologically relevant systems for understanding human responses in healthy and disease states; and provides human vascular systems, including artery systems, arteriole and microvascular systems, advanced inflammatory systems, atherosclerosis-prone cond...

1115 5th Street SW

Charlottesville, VA 22902

United States

Founded in 2008

Phone:

434-872-0196

Fax:

434-872-0199

Key Executives for HemoShear, LLC

Chairman and Chief Executive Officer
Age: 63
President and Member of Board of Managers
Co-Founder, Chief Scientific Officer and Director
Co-Founder, Vice President of Research & Development and Director
Vice Chairman, Chief Financial Officer and Chairman of Audit Committee
Compensation as of Fiscal Year 2015.

HemoShear, LLC Key Developments

HemoShear Names Vincent E. Aurentz as President

HemoShear announced that Vincent E. Aurentz, Chief Business Officer, has been named President of HemoShear. Mr. Aurentz will be responsible for leading HemoShear's scientific and business development strategies, as well as public relations and marketing, in addition to his existing business development responsibilities. He will continue to report directly to CEO and Chairman Jim Powers, and will also join HemoShear's Board of Managers. Mr. Aurentz's appointment will utilize his more than 25 years of experience in the pharmaceutical and biotech industry as an entrepreneur and pharmaceutical R&D executive. He spent almost nine years with Merck KGaA and Merck Serono where he was Executive Vice President, Portfolio Development and member of the Executive Management Board as well as Head of Global Business Development. He was also recently Executive Vice President at Quintiles.

HemoShear Completes First Phase of Development of Novel Cancer Drug Discovery Platform

HemoShear announced that it has completed the first phase of development of a novel cancer drug discovery platform that replicates human tumor biology and responds to clinically-relevant drug concentrations. Funded by a contract with the NCI, HemoShear is developing a series of tumor models that recreate a wide variety of cancers for discovery of new drugs. Using their new platform, HemoShear was able to successfully replicate human therapeutic response to Cisplatin, a drug approved to treat non-small cell lung carcinomoa, at a therapeutically-relevant concentration. Similarly, HemoShear evaluated two other drugs currently in clinical studies and confirmed a therapeutic response. When evaluated in traditional cell culture systems and mouse studies, the same dose of Cisplatin does not show a response. HemoShear's findings reinforce the need to test cancer drug candidates under more human-relevant tumor conditions. HemoShear's translational tissue systems apply physiological blood flow characteristics to human tissue to restore its in vivo biology, using material from HemoShear's biorepository and interpreting data with cutting edge computational analytics. In phase I of the NCI-funded program, HemoShear demonstrated that NSCLC tumor structure, biology, and molecular signaling pathways are restored in the HemoShear platform.

HemoShear, LLC Presents at BIO International Convention, Jun-23-2014 through Jun-26-2014

HemoShear, LLC Presents at BIO International Convention, Jun-23-2014 through Jun-26-2014. Venue: San Diego Convention Center, San Diego, California, United States. Presentation Date & Speakers: Jun-24-2014, Vincent Aurentz, Chief Business Officer. Jun-25-2014, Brian R. Wamhoff, Co-Founder, Vice President of Research & Development and Director.

Similar Private Companies By Industry

Company Name Region
DUSA Pharmaceuticals Inc. United States
Bionet Technologies, Inc. United States
Forelight, Inc. United States
CSL Behring LLC United States
Csl Us Inc United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HemoShear, LLC, please visit www.hemoshear.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.